window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 25, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

UCB

  • Digital & Data

    UCB adopts Veeva Safety Suite to unify global pharmacovigilance operations

    UCB has standardised its global pharmacovigilance operations on Veeva Safety [...]

    June 10, 2026
  • Clinical & Regulatory,Therapeutic Areas

    UCB reports positive phase 3 Gemz results as fenfluramine cuts seizure frequency in CDKL5 deficiency disorder

    UCB has reported positive findings from the Gemz phase 3 [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Bionyra launches with $165M Series A to advance immunology biologics pipeline
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • Atsena advances gene therapy ATSN-201 into Phase 3 trial for inherited blindness
    Categories: Advanced Therapies, Clinical & Regulatory, Genomics and sequencing, Therapeutic Areas
  • Pierre Fabre wins EU approval for first-line BRAFTOVI regimen in BRAF-mutant colorectal cancer
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top